4.5 Article

Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study

期刊

INFLAMMATORY BOWEL DISEASES
卷 23, 期 8, 页码 272-277

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000001211

关键词

ulcerative colitis; colectomy; predicators; inflammatory bowel disease

资金

  1. GlaxoSmith Kline
  2. Abbvie
  3. Shire
  4. Merck
  5. Schering-Plough
  6. Abbott Laboratories
  7. Elan Pharmaceuticals
  8. Procter and Gamble
  9. Bristol Meyers Squibb
  10. Millennium Pharmaceuticals
  11. Ferring
  12. Axcan
  13. Jansen
  14. UCB Canada
  15. Pfizer
  16. Pendopharm
  17. Takeda

向作者/读者索取更多资源

Background: A subset of patients with ulcerative colitis (UC) will require colectomy within a few years of diagnosis. Thus, our aim was to determine the clinical predictors of early colectomy among patients with UC who are hospitalized with an acute flare. Methods: Using population-based surveillance (1996-2009), all adults (>= 18 years) hospitalized for UC within 3 years of diagnosis (n = 489) were identified. The primary outcome was a colectomy within 3 years of diagnosis. All medical charts were reviewed. A logistic regression model evaluated clinical variables that predicted colectomy within 3 years of diagnosis, and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Results: Among patients admitted to hospital with UC within 3 years of diagnosis, 57.7% underwent colectomy, with the odds of colectomy decreasing by 12% per year. Early colectomy was more likely among patients aged 35 to 64 years versus 18 to 34 years (OR 2.18 [95% CI, 1.27-3.74]), males (OR 2.03 [95% CI, 1.24-3.34]), those with pancolitis (OR 5.38 [95% CI, 3.20-9.06]), and living in rural areas (OR 2.81 [95% CI, 1.49-5.29]). Prescription of infliximab before hospitalization increased odds of surgery (OR 5.12 [95% CI, 1.36-19.30]). Conclusions: Patients hospitalized for UC have a high risk of early colectomy. This is particularly true in middle-aged men, those living in rural areas, and those without response to infliximab.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire

Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio Del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose G. Ferraz, Martin Goetz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarey, Remo Panaccione, Adolfo Parra-Blanco, Luca Pastorelli, Timo Rath, Elin S. Royset, Gian Eugenio Tontini, Michael Vieth, Davide Zardo, Subrata Ghosh, Valery Naranjo, Vincenzo Villanacci

Summary: An artificial intelligence computer-aided diagnosis system was developed and validated to evaluate UC biopsies and predict prognosis. The system showed high accuracy and sensitivity in assessing biopsy results and predicting outcomes.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis

Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q. Huynh, Anne M. Griffiths, Dan Turner, Karen L. Madsen, Paul Moayyedi, A. Hillary Steinhart, Mark S. Silverberg, Colette Deslandres, Alain Bitton, David R. Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N. Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru

Summary: This study identified serum proteomic signatures associated with future development of Crohn's disease (CD), reflecting potential early biological processes of immune and barrier dysfunction.
Article Gastroenterology & Hepatology

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study

Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan

Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey

Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione

Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data

Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione

Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.

INFLAMMATORY BOWEL DISEASES (2023)

Review Gastroenterology & Hepatology

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions

Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne

Summary: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, is a condition characterized by uncontrolled inflammation in the gastrointestinal tract. Artificial intelligence is increasingly being used to provide accurate evaluations of endoscopic appearance and histologic activity in patients with inflammatory bowel disease. These AI tools also have the potential to predict treatment response to biologic therapies and improve the standard of care, by personalizing treatment options and reducing costs.

INTESTINAL RESEARCH (2023)

Review Gastroenterology & Hepatology

Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis

Sudheer Kumar Vuyyuru, Virginia Solitano, Malcolm Hogan, John K. MacDonald, Alexa Zayadi, Claire E. Parker, Bruce E. Sands, Remo Panaccione, Neeraj Narula, Brian G. Feagan, Siddharth Singh, Vipul Jairath, Christopher Ma

Summary: This systematic review and meta-analysis evaluated the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD. The results demonstrated that targeting IL-23 is effective and safe for inducing and maintaining clinical and endoscopic remission.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis

Simon Travis, Alison Potts Bleakman, Marla C. Dubinsky, Stefan Schreiber, Remo Panaccione, Toshifumi Hibi, Theresa Hunter Gibble, Cem Kayhan, Christian Atkinson, Christophe Sapin, Eoin J. Flynn, David T. Rubin

Summary: Bowel urgency has a significant impact on the lives of patients from the United States and Europe, and there are disparities between patient and healthcare professional perceptions on the experience and impact of ulcerative colitis symptoms. The CONFIDE study aimed to evaluate these symptoms and communication gaps between patients and healthcare professionals in the US and Europe.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study

Sangmin Lee, Cynthia H. Seow, Kara Nerenberg, Stefania Bertazzon, Yvette Leung, Vivian Huang, Tara Whitten, Stephanie Coward, Remo Panaccione, Gilaad G. Kaplan, Amy Metcalfe

Summary: Attendance at a dedicated IBD-pregnancy clinic improves disease-specific pregnancy knowledge and does not affect perinatal outcomes in pregnant women with IBD.

INFLAMMATORY BOWEL DISEASES (2023)

Meeting Abstract Gastroenterology & Hepatology

Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

R. Atreya, P. Irving, M. Fujiya, J. F. Colombel, S. Danese, L. Peyrin-Biroulet, T. Bessissow, R. Panaccione, G. D'Haens, S. van Haaren, E. Neimark, J. Zambrano, Y. Zhang, K. Kligys, M. Ferrante

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studies

R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire

Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Correction Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (Sep, jjac141, 2022)

William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes

JOURNAL OF CROHNS & COLITIS (2023)

暂无数据